Advertisement
UK markets close in 6 hours 38 minutes

  • FTSE 100

    8,041.58
    +17.71 (+0.22%)
     

  • FTSE 250

    19,682.57
    +83.18 (+0.42%)
     

  • AIM

    751.71
    +2.53 (+0.34%)
     

  • GBP/EUR

    1.1594
    +0.0005 (+0.04%)
     

  • GBP/USD

    1.2377
    +0.0026 (+0.21%)
     

  • Bitcoin GBP

    53,466.07
    +76.20 (+0.14%)
     

  • CMC Crypto 200

    1,392.79
    -21.97 (-1.55%)
     

  • S&P 500

    5,010.60
    +43.37 (+0.87%)
     

  • DOW

    38,239.98
    +253.58 (+0.67%)
     

  • CRUDE OIL

    82.79
    +0.89 (+1.09%)
     

  • GOLD FUTURES

    2,317.90
    -28.50 (-1.21%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • HANG SENG

    16,828.93
    +317.24 (+1.92%)
     

  • DAX

    17,969.36
    +108.56 (+0.61%)
     

  • CAC 40

    8,062.14
    +21.78 (+0.27%)
     
Money:

What is the true cost of the UK state pension?

To get a sense of the true value of the state pension, you can look at how much you would need to save to match it yourself

COVID-19 vaccine developers prepare joint safety pledge - WSJ

Reuters
·1-min read
FILE PHOTO: Small bottles labeled with a "Vaccine COVID-19" sticker and a medical syringe are seen in this illustration

(Reuters) - Several COVID-19 vaccine developers, including Pfizer Inc <PFE.N>, Johnson & Johnson <JNJ.N> and Moderna Inc <MRNA.O>, plan to issue a public pledge not to seek government approval until their vaccine candidates are proven to be safe and effective, the Wall Street Journal reported on Friday.

The companies would pledge to adhere to high scientific and ethical standards in the conduct of clinical studies and in their manufacturing processes, the Journal report said, citing the draft of a joint statement that is still being finalized.

The companies might issue the pledge as soon as early next week, the report added, citing two people familiar with the matter.

The news comes amid rising concerns that political pressure ahead of the Nov. 3 election could weigh on the safety and effectiveness of a potential vaccine for the respiratory illness.

ADVERTISEMENT

White House Press Secretary Kayleigh McEnany said on Thursday that even though the stakes are high for President Donald Trump, who is squaring off against former Vice President Joe Biden, there is no political pressure on the U.S. health regulator to quickly approve a vaccine.

AstraZeneca Plc <AZN.L>, Pfizer and Moderna are among those farthest along in the race to develop vaccines to prevent COVID-19 infection or limit its severity, with their candidates in late-stage clinical trials.

Pfizer, Moderna and Johnson & Johnson did not immediately respond to Reuters request for comment.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Vinay Dwivedi)